CAR-T therapy survivors monitored for Long-Term safety and survival
Knowledge-focused
Not yet recruiting
This study follows up to 49 people with relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who previously received ARD103 CAR-T cell therapy in an earlier trial. Researchers will track side effects, overall survival, and how long any response lasts. The goal …
Sponsor: ARCE Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC